RE: Hypothetical valuation?
And, if I can add one more attribute of this focussed biotech company Zep is envisioning....it understands the value of factual and supportive ongoing communication with investors and future investors. And, the needs of the intermediaries that bring the two together.
For example, current reports mentioning MCC would be found on their professionally designed web site on a side bar of the home page (not hidden away). Such as the report below that was helpful for me to understand the available treatments (many still in development). Would have been handy as a primer just as Phase IIIa results were being released. A report entitled "Recognition and treatment of BCG Failure in Bladder Cancer", published by three American urologists in March 2011 but did not include Urocidin's phIIIa results. And, a third party report no less.
An excerpt from the report, found in the Summary section..."The most promising immunotherapies currently available include BCG in combination with IFN-a2b and MCC."
https://www.tswj.com/2011/825490/abs/ and, if opened, hit thetab for Full-text PDF, in upper right of page.
I digress, but hopefully the above report is also helpful for other posters. rg